cu-64 sartate
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 9, 2018 (NCT03936426)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Somatostatin receptorRadiopharmaceutical
Somatostatin receptor radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 64-copper
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03936426 | Phase 1/Phase 2 (Phase 2) | Jul 9, 2018 | Clarity Pharmaceuticals Ltd, University of Sydney |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clarity Pharmaceuticals Ltd | For profit | 1 | 1 | 1 | 2018 |
| University of Sydney | Academic/Hospital | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1